Results for the First Quarter 2022

All-time high sales for a quarter ending at MNOK 116.1 (MNOK 102.6), an increase of 13.2%. Sales growth is driven by the USA with a currency-neutral increase of 34.2%. Currency neutral sales of own products…

Read more

Annual Report 2021

This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…

Read more

Results for the Third Quarter 2021

Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…

Read more

Annual Report 2020

Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…

Read more